Collegium (COLL) Xtampza ER Sales More than Double Expectations - William Blair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Collegium Reports Third Quarter Financial Results and Provides Corporate Update
November 8, 2017 4:01 PM ESTXtampza® ER prescriptions grow by 49% in the third quarterFDA Approval of sNDA, including Comparative OxyContin DataStrong balance sheet provides cash runway into mid-2019 Conference call scheduled for today at 4:30 p.m. ET
CANTON, Mass., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the third quarter of 2017 and provided a corporate update.Â
We are encouraged by the continued adoption of Xtampza ER with consistent prescription growth during the third quarter, said Michael... More
